Connection
Jeffrey Goldstein to Polymorphism, Restriction Fragment Length
This is a "connection" page, showing publications Jeffrey Goldstein has written about Polymorphism, Restriction Fragment Length.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.053 |
|
|
|
-
Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, Brosen K, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Goldstein JA. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther. 1999 Aug; 290(2):635-40.
Score: 0.044
-
Blaisdell J, Goldstein JA, Bai SA. Isolation of a new canine cytochrome P450 CDNA from the cytochrome P450 2C subfamily (CYP2C41) and evidence for polymorphic differences in its expression. Drug Metab Dispos. 1998 Mar; 26(3):278-83.
Score: 0.010